Table 1. “Detailed immunogenetic, genetic and cell phenotype information of the PCL12 cell line and comparison to the respective properties of the MEC1 and MEC2 cell lines,” is missing a column.
Please see the corrected Table 1 here.
| PCL12 | MEC1 | MEC2 | ||
|---|---|---|---|---|
| Immunogenetics | IGH rearrangement | V3-30-3 | D2-15 | J6 | V4-59 | D2-21 | J4 | |
| IGHV mutation status | 100% | 94.65% | ||
| VH CDR3 | AREGALAGDIVVVVAANYYYYYGMDV | ARSQGVLTAIDY | ||
| VH CDR3 length | 26 | 12 | ||
| IGL rearrangement | Igλ (V2-8 | J2/3) | Igκ (V4-1 | J2) | ||
| Genetics | NOTCH1 | no mutations | c.7544_7545delCT | - |
| SF3B1 | no mutations | no mutations | - | |
| TP53 | R72 polymorphism | R72 polymorphism | - | |
| c.521C>G, p.P174T | c.949_950insC | - | ||
| MYD88 | no mutations | no mutations | - | |
| del17p13 | no | yes | - | |
| Cell markers | CD5 | 95% | 0% | 0% |
| CD10 | 0% | 0% | 0% | |
| CD19 | 100% | 99% | 99% | |
| CD20 | 92% | 96% | 96% | |
| CD22 | 98% | 76% | 67% | |
| CD23 | 90% | 89% | 36% | |
| CD27 | 98% | 99% | - | |
| CD38 | 78% | 90% | 99% | |
| CD45 | 97% | 99% | 92% | |
| CD80 | 35% | 98% | 91% | |
| CD83 | 40% | 4% | - | |
| CD95 | 90% | 90% | 63% | |
| CD200 | 26% | 0% | - | |
| IgD | 54% | 97% | 99% | |
| IgM | 50% | 99% | 94% | |
| HLA-DR | 43% | 99% | 97% | |
| FMC7 | 0% | 8% | 72% | |
| ZAP70 | 37% | 18% | - | |
| CXCR4 | 9% | 5% | - | |
| CXCR5 | 42% | 12% | - | |
| VLA4 | 90% | 98% | - | |
| CD54 | 72% | 98% | 98% | |
| p-ERK | 87% | Positive WB 28 | - | |
Reference
- 1. Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MTS, Ranghetti P, et al. (2015) Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. PLoS ONE 10(6): e0130195 doi:10.1371/journal.pone.0130195 [DOI] [PMC free article] [PubMed] [Google Scholar]